1:00 PM (PT)
-
This opening session of the 2026 BIO AI Summit will provide the latest data from Benchling on AI adoption rates across the biotechnology industry including benchmarks by size of organization, by degre ...AI Summit Session
-
AI and Digital Health
-
)
1:45 PM (PT)
-
Real world data (RWD) are increasingly relied upon to inform drug policy decisions at both the state and federal levels. For example, state Prescription Drug Affordability Boards (PDABs) are using all ...Breakout Session
-
Value, Patient Access and Reimbursement
-
-
This session brings together leaders from pharma, AI technology, life sciences platforms, CROs, and specialized biotech AI to cut through the noise and examine how artificial intelligence is deliverin ...AI Summit Session
- AI and Digital Health
-
-
Within the Asia Pacific Region, Google Health and Health2Sync have partnered with Taiwan's National Health Insurance Administration and AI to stratify diabetes patients at risk of complications and th ...AI Summit Session
- AI and Digital Health
-
)
)
)
)
)
)
)
)
)
)
.jpeg)
)
2:45 PM (PT)
-
BrainStorm Therapeutics is a precision neuroscience company developing disease-modifying therapies for rare and neurodegenerative brain disorders. We integrate patient-derived brain organoids with AI ...Start-Up Stadium Session
-
Brain Health
-
3:00 PM (PT)
-
As technology evolves and AI requires more data to improve R&D productivity, the question largely becomes how much do we need versus how much do we want and subsequently, what are the unintended risks ...AI Summit Session
- AI and Digital Health
-
-
Generative genomics, using generative AI models to create entirely new, high-fidelity genomic data, represents a major shift in how we understand and apply biology. Large-scale AI models trained on ge ...AI Summit Session
- AI and Digital Health
-
)
)
)
)
)
)
)
)
)
)
)
)
)
4:15 PM (PT)
-
This session will explore how quantum computing is poised to redefine the frontiers of drug discovery by solving complex molecular and optimization problems that exceed the limits of classical computi ...AI Summit Session
- AI and Digital Health
-
-
Clinical trials for large-population diseases face persistent challenges and remain the most complex and resource-intensive steps in drug development. Patient recruitment often lags, administrative bo ...AI Summit Session
- AI and Digital Health
-
)
)
)
)
)
)
11:00 AM (PT)
-
The next evolution of AI in biopharma is already here - systems designed not just to analyze data but to make decisions. These “agentic AI” models can set goals, adapt strategies, and generate hypothe ...Breakout Session
- AI and Digital Health
-
-
AI has generated substantial interest across the life sciences industry, yet its practical adoption in commercial forecasting and early asset assessments remains limited. Many organizations continue t ...Breakout Session
-
Business Development and Investment
-
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
11:20 AM (PT)
-
Palo Alto Immunotherapeutics (PAI) is developing advanced immunotherapies for the treatment of cancer. Cancer vaccines have centered around identifying mutant proteins as the target with little regard ...Start-Up Stadium Session
-
Oncology
-
11:55 AM (PT)
-
Sift is a preclinical-stage biotechnology company using AI and high-throughput T-cell screening to develop peptide immunotherapies for cancer and autoimmune disease. Founded in 2024 as a UC Berkeley s ...Start-Up Stadium Session
- Oncology
-
1:45 PM (PT)
-
AI is redefining what’s possible across industries, and nowhere is the opportunity greater than in life sciences. But unlocking its full power requires more than algorithms — it demands bold new ways ...Breakout Session
- AI and Digital Health
-
-
Precision medicine has transformed oncology, but the next wave is unfolding in new therapeutic areas. The expansion into new areas promises enormous impact, yet the path forward is not straightforward ...Breakout Session
-
Diagnostics and Personalized Medicine
-
)
)
)
)
)
)
)
)
)
3:00 PM (PT)
-
AI-enabled discovery and multimodal, human-centric datasets are reshaping how biopharma and digital health companies differentiate, partner, and scale. Rather than focusing on capital trends, this ses ...Breakout Session
- AI and Digital Health
-
-
AI is becoming ubiquitous in biopharma, but no company can unlock its full potential alone. As the industry shifts from "tell me" to "show me," the pressure is on to move beyond the hype and use AI to ...Breakout Session
- AI and Digital Health
-
)
)
)
)
)
)
)
)
4:15 PM (PT)
-
AI-enabled discovery and multi-modal, human-centric datasets are driving the next wave of biopharma partnerships. Collaborations are expanding rapidly, characterized by larger upfronts, equity-linked ...Breakout Session
- Business Development and Investment
-
-
Cancer immunotherapy has transformed oncology, yet many patients still don't respond or develop resistance to these treatments. Meanwhile, AI has generated unprecedented libraries of potential targets ...Breakout Session
- AI and Digital Health
-
)
)
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
.jpeg)
)
9:00 AM (PT)
-
This year, Genentech celebrates its 50th anniversary—a milestone that marks not only the founding of the company, but the birth of the biotechnology industry itself. To mark this moment, join a dynami ...Featured Program
-
Special Program
-
.jpg/fit-in/64x9999/filters:no_upscale())
)
)
9:30 AM (PT)
-
This presentation describes the progress of a stem-cell therapeutic & commercial development from phase 3 and lessons learned. Specific challenges existing within the stem cell therapeutics and regene ...BioProcess Session BioProcess Theatre
)
11:00 AM (PT)
-
AI has moved from concept to execution in drug discovery, but turning algorithms into actionable insights requires deep scientific alignment and cross-functional integration. This session brings toget ...Breakout Session
- AI and Digital Health
-
-
Federated learning is a machine learning approach that trains models across decentralized datasets without pooling patient-level data into a central repository. For biotechnology executives, it can ac ...Breakout Session
- AI and Digital Health
-
)
.jpeg)
)
)
11:10 AM (PT)
1:45 PM (PT)
-
Although artificial intelligence (AI) has existed for decades, recent advances in computational power, data availability, and machine learning models have significantly accelerated its development and ...Breakout Session
- AI and Digital Health
-
-
For centuries, nature, and particularly the innate immune system, has encoded powerful mechanisms for disease control and repair. Today, artificial intelligence (AI) is reshaping drug discovery by rev ...Breakout Session
- AI and Digital Health
-
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
)
)
2:10 PM (PT)
-
This presentation explores practical applications of artificial intelligence across biopharmaceutical CMC, focusing on real-world use in GMP environments. It highlights AI-driven approaches to QMS, de ...BioProcess Session BioProcess Theatre
.jpg/fit-in/120x9999/filters:no_upscale())
3:00 PM (PT)
-
Until recently, drug discovery has been limited by fundamental practical constraints such as the range of proteins that exist in nature or the availability of samples, time, and funding for experiment ...Breakout Session
- AI and Digital Health
-
-
AI technologies are no longer a peripheral concept in drug discovery – these platforms are a driving force for innovative companies reshaping the way we identify targets, and design, optimize, and val ...Breakout Session
- AI and Digital Health
-
)
)
)
.jpg/fit-in/64x9999/filters:no_upscale())
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
4:15 PM (PT)
-
Artificial intelligence (AI) has become a widely used label across biotech companies positioning platforms for drug discovery and development. However, what truly defines an AI-marketed platform today ...Breakout Session
- AI and Digital Health
-
-
Death of expertise in the dawn of AI has been vastly overreported with no sign of its ability to displace creative and disciplined drug discovery teams. Citing Bernstein Research, the Financial Times ...Breakout Session
- AI and Digital Health
-
-
Back by popular demand, this session returns with fresh insights for 2026. Health and science executives will learn how to build and deliver an investor-ready story using LaVoieHealthScience’s LHS Fif ...Breakout Session
- Business Development and Investment
-
)
)
)
)
)
)
)
9:00 AM (PT)
-
Long before immunotherapy took center stage, it lived on the margins of oncology. Those pursuing it were often politely dismissed as “dreamers,” relegated to the back rooms at ASCO as well-intentioned ...Breakout Session
- Oncology
-
)
)
)
10:40 AM (PT)
-
Ursa Science builds a portable, bench-scale modular wet lab platform with an AI agent layer that adopts commercial off-the-shelf lab instruments as native modules within a unified, AI-orchestrated sys ...Start-Up Stadium Session
- Tools/Drug Development Support Tech
11:10 AM (PT)
-
Bullseye has built a fully automated engine to create medicines that unlock targets and diseases the biopharma industry has written off as impossible and “undruggable.” By harnessing biology’s most pr ...Start-Up Stadium Session
- Tools/Drug Development Support Tech
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}